Pediatric asthma: an unmet need for more effective, focused treatments

Nikolaos G Papadopoulos; Adnan Čustović; Michael D. Cabana; Philip R. Lee; Sharon D. Dell; Antoine Deschildre; Gunilla Hedlin; Elham Hossny; Peter Le Souëf; Paolo M. Matricardi; Antonio Nieto; Wanda Phipatanakul; Paulo M. Pitrez; Petr Pohunek; Marcela Gavornikova; Xavier Jaumont; David B Price

doi:10.1111/pai.12990

Pediatric asthma: an unmet need for more effective, focused treatments

Nikolaos G Papadopoulos (Corresponding Author), Adnan Čustović, Michael D. Cabana, Philip R. Lee, Sharon D. Dell, Antoine Deschildre, Gunilla Hedlin, Elham Hossny, Peter Le Souëf, Paolo M. Matricardi, Antonio Nieto, Wanda Phipatanakul, Paulo M. Pitrez, Petr Pohunek, Marcela Gavornikova, Xavier Jaumont, David B Price

Research output: Contribution to journal › Review article › peer-review

48 Citations (Scopus)

16 Downloads (Pure)

Abstract

BACKGROUND: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma.

METHODS: A two-day, face-to-face, meeting was held in London, United Kingdom, on 28th and 29th October 2017 involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma.

RESULTS: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients.

CONCLUSIONS: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies, may delay disease progression, leading to improved clinical outcomes. This article is protected by copyright. All rights reserved.

Original language	English
Pages (from-to)	7-16
Number of pages	10
Journal	Pediatric Allergy & Immunology
Volume	30
Issue number	1
Early online date	15 Nov 2018
DOIs	https://doi.org/10.1111/pai.12990
Publication status	Published - Feb 2019

Bibliographical note

The authors acknowledge Pascal Pfister for his support during the development of this manuscript. The authors also thank Gillian Lavelle PhD, of Novartis Product Lifecycle Services, Dublin, Ireland for providing medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

Keywords

asthma management
omalizumab
pediatric asthma
unmet need
Humans
United Kingdom
Asthma/drug therapy
Glucocorticoids/therapeutic use
Omalizumab/adverse effects
Health Services Needs and Demand
Delivery of Health Care/methods
Adolescent
Anti-Asthmatic Agents/adverse effects
Child
Practice Guidelines as Topic
OMALIZUMAB
BONE-MINERAL DENSITY
INHALED CORTICOSTEROIDS
PREDICTIVE-VALUE
IGE RESPONSES
ALLERGIC-ASTHMA
MANAGEMENT
CHILDHOOD
CHILDREN
DOUBLE-BLIND

Access to Document

10.1111/pai.12990Licence: CC BY-NC

Pediatric asthma
© 2018 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. https://creativecommons.org/licenses/by-nc/4.0/
Final published version, 508 KBLicence: CC BY-NC

Cite this

Papadopoulos, N. G., Čustović, A., Cabana, M. D., Lee, P. R., Dell, S. D., Deschildre, A., Hedlin, G., Hossny, E., Le Souëf, P., Matricardi, P. M., Nieto, A., Phipatanakul, W., Pitrez, P. M., Pohunek, P., Gavornikova, M., Jaumont, X., & Price, D. B. (2019). Pediatric asthma: an unmet need for more effective, focused treatments. Pediatric Allergy & Immunology, 30(1), 7-16. https://doi.org/10.1111/pai.12990

Papadopoulos, NG, Čustović, A, Cabana, MD, Lee, PR, Dell, SD, Deschildre, A, Hedlin, G, Hossny, E, Le Souëf, P, Matricardi, PM, Nieto, A, Phipatanakul, W, Pitrez, PM, Pohunek, P, Gavornikova, M, Jaumont, X & Price, DB 2019, 'Pediatric asthma: an unmet need for more effective, focused treatments', Pediatric Allergy & Immunology, vol. 30, no. 1, pp. 7-16. https://doi.org/10.1111/pai.12990

@article{b1e46564377945059b6b3ec9d8c02e65,

title = "Pediatric asthma: an unmet need for more effective, focused treatments",

abstract = "BACKGROUND: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma.METHODS: A two-day, face-to-face, meeting was held in London, United Kingdom, on 28th and 29th October 2017 involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma.RESULTS: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients.CONCLUSIONS: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies, may delay disease progression, leading to improved clinical outcomes. This article is protected by copyright. All rights reserved.",

keywords = "asthma management, omalizumab, pediatric asthma, unmet need, Humans, United Kingdom, Asthma/drug therapy, Glucocorticoids/therapeutic use, Omalizumab/adverse effects, Health Services Needs and Demand, Delivery of Health Care/methods, Adolescent, Anti-Asthmatic Agents/adverse effects, Child, Practice Guidelines as Topic, OMALIZUMAB, BONE-MINERAL DENSITY, INHALED CORTICOSTEROIDS, PREDICTIVE-VALUE, IGE RESPONSES, ALLERGIC-ASTHMA, MANAGEMENT, CHILDHOOD, CHILDREN, DOUBLE-BLIND",

author = "Papadopoulos, {Nikolaos G} and Adnan {\v C}ustovi{\'c} and Cabana, {Michael D.} and Lee, {Philip R.} and Dell, {Sharon D.} and Antoine Deschildre and Gunilla Hedlin and Elham Hossny and {Le Sou{\"e}f}, Peter and Matricardi, {Paolo M.} and Antonio Nieto and Wanda Phipatanakul and Pitrez, {Paulo M.} and Petr Pohunek and Marcela Gavornikova and Xavier Jaumont and Price, {David B}",

note = "The authors acknowledge Pascal Pfister for his support during the development of this manuscript. The authors also thank Gillian Lavelle PhD, of Novartis Product Lifecycle Services, Dublin, Ireland for providing medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).",

year = "2019",

month = feb,

doi = "10.1111/pai.12990",

language = "English",

volume = "30",

pages = "7--16",

journal = "Pediatric Allergy & Immunology",

issn = "0905-6157",

publisher = "Blackwell Munksgaard",

number = "1",

}

TY - JOUR

T1 - Pediatric asthma

T2 - an unmet need for more effective, focused treatments

AU - Papadopoulos, Nikolaos G

AU - Čustović, Adnan

AU - Cabana, Michael D.

AU - Lee, Philip R.

AU - Dell, Sharon D.

AU - Deschildre, Antoine

AU - Hedlin, Gunilla

AU - Hossny, Elham

AU - Le Souëf, Peter

AU - Matricardi, Paolo M.

AU - Nieto, Antonio

AU - Phipatanakul, Wanda

AU - Pitrez, Paulo M.

AU - Pohunek, Petr

AU - Gavornikova, Marcela

AU - Jaumont, Xavier

AU - Price, David B

N1 - The authors acknowledge Pascal Pfister for his support during the development of this manuscript. The authors also thank Gillian Lavelle PhD, of Novartis Product Lifecycle Services, Dublin, Ireland for providing medical writing support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

PY - 2019/2

Y1 - 2019/2

N2 - BACKGROUND: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma.METHODS: A two-day, face-to-face, meeting was held in London, United Kingdom, on 28th and 29th October 2017 involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma.RESULTS: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients.CONCLUSIONS: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies, may delay disease progression, leading to improved clinical outcomes. This article is protected by copyright. All rights reserved.

AB - BACKGROUND: Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma.METHODS: A two-day, face-to-face, meeting was held in London, United Kingdom, on 28th and 29th October 2017 involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma.RESULTS: These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non-steroid-based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients.CONCLUSIONS: There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real-world evidence studies assessing anti-immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti-IgE and non-steroid-based alternative therapies, may delay disease progression, leading to improved clinical outcomes. This article is protected by copyright. All rights reserved.

KW - asthma management

KW - omalizumab

KW - pediatric asthma

KW - unmet need

KW - Humans

KW - United Kingdom

KW - Asthma/drug therapy

KW - Glucocorticoids/therapeutic use

KW - Omalizumab/adverse effects

KW - Health Services Needs and Demand

KW - Delivery of Health Care/methods

KW - Adolescent

KW - Anti-Asthmatic Agents/adverse effects

KW - Child

KW - Practice Guidelines as Topic

KW - OMALIZUMAB

KW - BONE-MINERAL DENSITY

KW - INHALED CORTICOSTEROIDS

KW - PREDICTIVE-VALUE

KW - IGE RESPONSES

KW - ALLERGIC-ASTHMA

KW - MANAGEMENT

KW - CHILDHOOD

KW - CHILDREN

KW - DOUBLE-BLIND

UR - http://www.scopus.com/inward/record.url?scp=85056461048&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/pediatric-asthma-unmet-need-more-effective-focused-treatments

U2 - 10.1111/pai.12990

DO - 10.1111/pai.12990

M3 - Review article

C2 - 30312503

SN - 0905-6157

VL - 30

SP - 7

EP - 16

JO - Pediatric Allergy & Immunology

JF - Pediatric Allergy & Immunology

IS - 1

ER -

Pediatric asthma: an unmet need for more effective, focused treatments

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this